PATENT CLAIM ANALYSIS

Application Number: 16084668
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["424", "450000"]

Abstract:
Disclosed is an Edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a co-solvent based formulation.

Claim (Index 15):
The solid phase dispersion formulation of  claim 13 , wherein the surfactant is TPGS 1000.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15844365', '13884182', '12876292', '13707122', '13414369']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7358650196442723
- 35 USC 102 Novelty (BERT): 0.5078044149298108
- Combined Prediction Score: 0.7130589591728262
- Mean Citation Score: 214.404466
- Max Citation Score: 254.98409
- Similarity Product: 170.89673309504926

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test